The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers (RE-AGES)
Primary Purpose
Coronary Artery Disease, Menopause, Endothelial Dysfunction
Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Resveratrol
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary artery disease, Menopause, Endothelial Dysfunction, Sirtuin, Receptors of advanced glycation end products, Apoptosis, Resveratrol, Polyphenols, Cardiovascular risk
Eligibility Criteria
Inclusion Criteria: Postmenopausal women; Diagnosed coronary artery disease; Stable coronary disease; Exclusion Criteria: hypo or hyperthyroidism, rheumatic disease, use of alcohol, hepatic failure, renal failure hormone replacement therapy use of insulin
Sites / Locations
- INCOR- Heart InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Resveratrol
Control
Arm Description
Trans-resveratrol, 1000mg daily for 90 days.
Starch, 1000mg daily for 90 days.
Outcomes
Primary Outcome Measures
Sirtuin-1 and sirtuin-3
Serum concentrations and gene expression
Inhibitors of apoptosis proteins
Gene expression of Bcl-2, XIAP, c-IAP1, and survivin
sRAGE
Serum concentrations and gene expression
Secondary Outcome Measures
Inflammation
Serum concentrations of proinflammatory cytokines
Cardiometabolic risk factors
Lipid and glucometabolic profiles
Anthropometric measures
BMI, skinfold thickness, and body composition
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05808387
Brief Title
The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers
Acronym
RE-AGES
Official Title
The Effects of Resveratrol on Inhibitors of Apoptosis Proteins, on Soluble Receptors of Advanced Glycation End Products and on Sirtuins-1 and -3 in Postmenopausal Women With Coronary Artery Disease
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 6, 2023 (Actual)
Primary Completion Date
June 5, 2025 (Anticipated)
Study Completion Date
June 5, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
InCor Heart Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cardiovascular diseases (CVD) and neoplasms are the main causes of death in Brazilian women. Coronary artery disease (CAD) and stroke were responsible for approximately 54% of deaths from CVD in this population. In Brazil, cancers were the second cause of death and in 2017 were responsible for 58% of deaths in women. CVD and cancer share some risk factors, and control of these factors is associated with a significant reduction in cancer incidence. These two causes of death, although apparently disparate, share similar lifestyles and health risk factors, suggesting some common pathways and basic molecular networks. In women, the presence of estrogen has protective effects against atherosclerosis and, with the decline in hormone production at menopause, the incidence and prevalence of CAD increase substantially. Although the estrogen pathway is supposed to have a central effect on this increased risk, it is still debated whether other non-estrogenic mechanisms are related, since hormone replacement alone does not reduce cardiovascular events. Sirtuins and soluble advanced glycation product receptors (sRAGE) are associated with increased vascular protection, while the role of apoptosis inhibiting proteins, a pathway linked to increased cancer incidence, is still unclear in the context of atherosclerosis. Resveratrol is a key activator of sirtuins and potentially modulates these metabolic pathways, reducing cardiovascular risk. This randomized, double-blind, parallel, placebo-controlled clinical trial will be carried out in 80 postmenopausal women with CAD to analyze the effect of treatment with resveratrol on serum concentration and gene expression of sirtuins-1 -3, in the serum sRAGE concentration and in the gene expression of apoptosis inhibitory proteins.
Detailed Description
The objective of the study is to evaluate the influence of sirtuins stimulation by resveratrol on inhibitors of apoptosis proteins gene expression of circulation angiogenic cells of postmenopausal women with stable coronary artery disease.
A randomized, double-blind, parallel, placebo-controlled clinical trial in postmenopausal women with CAD submitted to 90 days of daily resveratrol supplementation days of daily supplementation with 1000 mg of resveratrol. Eighty women aged ≥55 years, with overweight or obesity grade 1 (BMI between 25 and 35 kg/m2) will be selected. The participants will be randomized into two groups, control (CON) and resveratrol (RES). After the screening, the participants will undergo the first clinical and laboratory evaluation including lipid and glucose metabolism, inflammatory biomarkers, serum concentrations and gene expression of sirtuin-1 and sirtuin-3 and soluble receptor of advanced glycation end products, and the gene expression of inhibitors of apoptosis proteins.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Menopause, Endothelial Dysfunction
Keywords
Coronary artery disease, Menopause, Endothelial Dysfunction, Sirtuin, Receptors of advanced glycation end products, Apoptosis, Resveratrol, Polyphenols, Cardiovascular risk
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Double blind randomized controlled trial, parallel and placebo-controlled.
Masking
ParticipantCare Provider
Masking Description
Participants in the control group will receive capsules identical to those in the intervention group, but with cornstarch.
The care provider and the participants do not have the information about which capsules the participant is taking, and do not have access to which groups the patients belong. Statistical analyses will be performed on a blinded database, i.e. without information of which groups the participants belong to.
Only the principal investigator of the study has this information.
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Resveratrol
Arm Type
Experimental
Arm Description
Trans-resveratrol, 1000mg daily for 90 days.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Starch, 1000mg daily for 90 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Resveratrol
Intervention Description
Trans-resveratrol, 1000 mg daily for 90 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Starch, 1000 mg daily for 90 days
Primary Outcome Measure Information:
Title
Sirtuin-1 and sirtuin-3
Description
Serum concentrations and gene expression
Time Frame
90 days
Title
Inhibitors of apoptosis proteins
Description
Gene expression of Bcl-2, XIAP, c-IAP1, and survivin
Time Frame
90 days
Title
sRAGE
Description
Serum concentrations and gene expression
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Inflammation
Description
Serum concentrations of proinflammatory cytokines
Time Frame
90 days
Title
Cardiometabolic risk factors
Description
Lipid and glucometabolic profiles
Time Frame
90 days
Title
Anthropometric measures
Description
BMI, skinfold thickness, and body composition
Time Frame
90 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Postmenopausal women;
Diagnosed coronary artery disease;
Stable coronary disease;
Exclusion Criteria:
hypo or hyperthyroidism,
rheumatic disease,
use of alcohol,
hepatic failure,
renal failure
hormone replacement therapy
use of insulin
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antonio P Mansur, PhD
Phone
551126615448
Email
apmansur@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonio P Mansur, PhD
Organizational Affiliation
InCor Heart Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
INCOR- Heart Institute
City
Sao Paulo
State/Province
São Paulo
ZIP/Postal Code
05403900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio de Pádua Mansur, PHD
Phone
26615387
Ext
11
Email
apmansur@yahoo.com
First Name & Middle Initial & Last Name & Degree
Antonio P Mansur, PhD
First Name & Middle Initial & Last Name & Degree
Gustavo HF Gonçalinho
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers
We'll reach out to this number within 24 hrs